SLC5A2 and type 2 diabetes mellitus: The European Medicines Agency (EMA) has authorized dapagliflozin (DAPA), the first novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor, to manage type 2 diabetes by blocking SGLT2.